English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Acute leukemias constitute the most common malignancy in childhood,   accounting for 25-35% of all cancer in children. They are divided into acute   lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). Genetic   susceptibility is known to play a major role in childhood leukemias. Wilms   tumor (WT)1 is a zinc finger transcription factor involved in regulating the   process of cell differentiation; it has been implicated in a wide range of   human neoplasms. WT1 overexpression in the bone marrow at diagnosis is   reported to be an independent negative prognostic factor in adults and   children with AML. The aim of the present investigation was to determine the   expression of WT1 in the bone marrow of children with AML and ALL in Serbia   and its possible impact on patient survival. We determined bone marrow WT1   expression levels by reverse-transcription polymerase chain reaction (RT-PCR)   at diagnosis in 20 children with AML and 20 children with ALL (16 B-ALL and 4   T-ALL), as well as 15 age- and sex-matched controls who were evaluated for   immune thrombocytopenic purpura (ITP). For children with AML, follow-up   samples were also analyzed one month after treatment initiation and at   variable later timepoints of control punctures. The results were normalized   based on WT1 expression in controls. We found that children with AML had   significantly higher WT1 expression at diagnosis (median ± SD: 139.42 ±   244.03) than those with ALL (1.18 ± 54.37; Mann-Whitney U=82; p<0.01) and ITP   (0.76 ± 1.01; U=32; p<0.01). Patients with T-ALL had higher WT1 expression   than those with B-ALL, though significance was not reached due to subgroup   size; differences between AML subgroups according to the   French-American-British (FAB) classification were also below the level of   significance, though a tendency toward higher values in M3 and M4 leukemias   was notable. There was also a tendency toward higher values in 14 children   with AML who were still alive after a median follow-up of 1.5 years (181.42 ±   192.52) than in 6 who succumbed to the disease (104.29 ± 354.87). All   children with AML who had WT1 expression 1 month after diagnosis below the   fourth quartile (10 of 10) were still alive, while only 2 of 5 with 1-month   WT1 expression in the fourth quartile survived (Fisher’s exact test:   p=0.0952). Taken together, our results support a role for WT1 in the   diagnostic workup in children with acute leukemia, although it needs to be   considered in view of a complex and indvidualized context. [Projekat   Ministarstva nauke Republike Srbije, br. 41004

Wilms tumor (WT)1 gene expression in children with acute leukemia in Serbia